Related Experiment Video
Updated: Sep 29, 2025

Tuning Degradation to Achieve Specific and Efficient Protein Depletion
Published on: July 20, 2019
The Role of ARID1A in the Nonestrogenic Modulation of IGF-1 Signaling
Sham Jdeed1, Edina Erdős2, Bálint L Bálint2
1Department of Clinical Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Abstract:
Gaining pharmacologic access to the potential of ARID1A, a tumor suppressor protein, to mediate transcriptional control over cancer gene expression is an unresolved challenge. Retinoid X receptor ligands are pleiotropic, incompletely understood tools that regulate breast epithelial cell proliferation and differentiation. We found that low-dose bexarotene (Bex) combined with the nonselective beta-blocker carvedilol (Carv) reduces proliferation of MCF10DCIS.com cells and markedly suppresses ARID1A levels. Similarly, Carv synergized with Bex in MCF-7 cells to suppress cell growth. Chromatin immunoprecipitation sequencing analysis revealed that under nonestrogenic conditions Bex + Carv alters the concerted genomic distribution of the chromatin remodeler ARID1A and acetylated histone H3K27, at sites related to insulin-like growth factor (IGF) signaling. Several distinct sites of ARID1A enrichment were identified in the IGF-1 receptor and IRS1 genes, associated with a suppression of both proteins. The knock-down of ARID1A increased IGF-1R levels, prevented IGF-1R and IRS1 suppression upon Bex + Carv, and stimulated proliferation. In vitro IGF-1 receptor neutralizing antibody suppressed cell growth, while elevated IGF-1R or IRS1 expression was associated with poor survival of patients with ER-negative breast cancer. Our study demonstrates direct impact of ARID1A redistribution on the expression and growth regulation of IGF-1-related genes, induced by repurposed clinical drugs under nonestrogenic conditions.
Implications:
This study underscores the possibility of the pharmacologic modulation of the ARID1A factor to downregulate protumorigenic IGF-1 activity in patients with postmenopausal breast cancer undergoing aromatase inhibitor treatment.
Insights
Repurposed drugs bexarotene and carvedilol suppress breast cancer growth by altering ARID1A protein levels and regulating insulin-like growth factor signaling pathways. This offers a new therapeutic strategy for breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- ARID1A is a tumor suppressor protein involved in cancer gene expression.
- Retinoid X receptor ligands affect breast cell proliferation and differentiation.
- Targeting ARID1A pharmacologically remains a challenge.
Purpose of the Study:
- To investigate the effect of bexarotene (Bex) and carvedilol (Carv) on ARID1A levels and breast cancer cell proliferation.
- To elucidate the mechanism by which Bex + Carv impacts gene expression, particularly related to insulin-like growth factor (IGF) signaling.
- To explore the therapeutic potential of modulating ARID1A activity in breast cancer.
Main Methods:
- Cell proliferation assays using MCF10DCIS.com and MCF-7 breast cancer cell lines.
- Western blotting to assess ARID1A protein levels.
- Chromatin immunoprecipitation sequencing (ChIP-seq) to analyze genomic distribution of ARID1A and H3K27ac.
- Gene knockdown experiments for ARID1A.
- In vitro assays using IGF-1 receptor neutralizing antibody.
Main Results:
- Low-dose Bex combined with Carv suppressed proliferation and reduced ARID1A levels in breast cancer cells.
- Bex + Carv altered the genomic distribution of ARID1A and H3K27ac at IGF signaling-related sites, suppressing IGF-1 receptor (IGF-1R) and IRS1.
- ARID1A knockdown increased IGF-1R levels and abrogated the suppressive effects of Bex + Carv, while stimulating proliferation.
- Elevated IGF-1R or IRS1 expression correlated with poor survival in ER-negative breast cancer patients.
Conclusions:
- ARID1A redistribution directly impacts the expression and growth regulation of IGF-1-related genes.
- Repurposed drugs Bex and Carv can induce ARID1A redistribution under nonestrogenic conditions.
- Pharmacologic modulation of ARID1A offers a potential strategy to downregulate protumorigenic IGF-1 activity in breast cancer.
Related Concept Videos
Regulation of the Unfolded Protein Response
TGF - β Signaling Pathway
Regulation of Angiogenesis and Blood Supply
The JAK-STAT Signaling Pathway
Cell Signaling in Plants
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...

